M Katharine Holloway

This inventor holds 17 USPTO granted patents and 3 published patent applications and 12 EPO patents, primarily in HIV Protease Inhibitors. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Hahnemann University. Active years: 1995-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: M Katharine Holloway. Retrieved from https://idiyas.com/inventor/m-katharine-holloway

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 100.0

EPO Patents = 12 (Patent Applications = 5)

Average Co-Inventor Count = 6.0

ph-index = 6

Forward Citations = 209(Granted Patents)

Company Filing History:

9 out of 2,405

Merck Sharp + Dohme Corp.

Msd R&d (China) Co., Ltd.

patents

6. 1 out of 11

The Medical College of Pennsylvania

patents

where one patent can have more than one assignee

Years Active: 1995-2018

Loading Chart...

Areas of Expertise:

Piperazine Derivatives

HIV Protease Inhibitors

Beta-Secretase Inhibitors

Alzheimer's Disease

HCV NS3 Protease Inhibitors

Transcription Activators

2-Aminopyridine Compounds

Spiropiperidine Compounds

AIDS Treatment

Macrocyclic Compounds

Protease Inhibitors

Therapeutic Agents

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10138255 - Piperazine derivatives as HIV protease inhibitors (2018-11-27),

2. 9994587 - HIV protease inhibitors (2018-06-12),

3. 9840478 - Piperazine derivatives as HIV protease inhibitors (2017-12-12),

4. 8497383 - HIV protease inhibitors (2013-07-30),

5. 8399473 - Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of Alzheimer's disease (2013-03-19),

6. 8278322 - HCV NS3 protease inhibitors (2012-10-02),

7. 8216999 - HCV NS3 protease inhibitors (2012-07-10),

8. 7932275 - 2-aminopyridine compounds useful as β-secretase inhibitors for the treatment of alzheimer's disease (2011-04-26),

9. 7879797 - HCV NS3 protease inhibitors (2011-02-01),

10. 7470664 - HCV NS3 protease inhibitors (2008-12-30),

11. 5846978 - HIV protease inhibitors useful for the treatment of AIDS (1998-12-08),

12. 5717097 - HIV protease inhibitors useful for the treatment of AIDS (1998-02-10),

13. 5679518 - Method for finding transcription activators of the NER steroid hormone (1997-10-21),

14. 5668132 - HIV Protease inhibitors useful for the treatment of AIDS (1997-09-16),

15. 5607967 - Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan (1997-03-04),

Title: Celebrating the Contributions of M. Katharine Holloway in the Field of HIV Research

Introduction: M. Katharine Holloway, a prolific inventor based in Lansdale, PA, has made significant strides in the field of medicinal chemistry and HIV research. With an impressive portfolio of 17 patents, her work focuses on developing innovative compounds aimed at combating HIV and improving patient outcomes for those affected by the virus.

Latest Patents: Among her latest innovations, Holloway has developed piperazine derivatives that act as inhibitors of HIV protease. These compounds hold promise in preventing HIV replication and are utilized in the treatment and prophylaxis of HIV infection, as well as in delaying the onset or progression of AIDS. Another notable invention includes 2,6-morpholine derivatives that also serve as HIV protease inhibitors. These compounds, along with their pharmaceutically acceptable salts, provide a foundation for producing effective pharmaceutical compositions, which may be combined with other treatments such as antivirals, immunomodulators, and vaccines.

Career Highlights: Holloway has had a distinguished career, contributing her expertise to renowned companies in the pharmaceutical industry, including Merck Sharp & Dohme Corporation and Merck & Company, Inc. Her innovative spirit and dedication to research have led to advancements in HIV treatment protocols and pharmaceutical applications.

Collaborations: Throughout her career, M. Katharine Holloway has collaborated with esteemed colleagues, including Joseph P. Vacca and John A. McCauley. Together, they have contributed to the development of effective therapeutic strategies to combat HIV, showcasing the importance of teamwork in scientific discovery.

Conclusion: M. Katharine Holloway's contributions to science and medicine have been invaluable, particularly in the fight against HIV. Her numerous patents are a testament to her innovative thinking and dedication to improving healthcare outcomes. As research continues to evolve, Holloway's work is poised to inspire future generations of inventors and scientists in the quest for medical advancements.

Profile summary based on public USPTO records.